RNF180 and gastric cancer: Besides, additional studies further suggested that the methylation of key CpG sites or hypermethylated CpG site count of RNF180 DNA promoter may predict the prognosis of gastric cancer patients in clinics.71,72 The MDM2 gene amplification is often observed in gastric cancer, potentially also contributing to this cancer tumorigenesis.73,74 As the tumors with MDM2 gene amplification respond well to MDM2 antagonists,42,75 MDM2 is a promising target for gastric cancer therapy.